查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球高脂血症市场（2022-2028 年）：按类型、治疗、分销渠道和地区划分的市场规模调查和预测
市场调查报告书
商品编码
1084067

全球高脂血症市场（2022-2028 年）：按类型、治疗、分销渠道和地区划分的市场规模调查和预测

Global Hyperlipidemia Market Size study, By Type, By Treatment, By Distribution Channel, and Regional Forecasts 2022-2028
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3个工作天内

价格

预计 2022-2028 年预测期内，全球高脂血症市场将以健康的增长率增长。主要的市场驱动因素包括高脂血症患病率的增加、医疗基础设施投资的增加以及老年人口的增加。然而，高昂的治疗成本和缺乏熟练的专业人员正在阻碍预测期内的市场增长。此外，研发活动的增加以及药物批准和上市的增加预计将在预测期内成为市场需求的催化剂。

本报告调查了全球高脂血症市场、市场概况、市场促进/抑制因素分析、市场机会、COVID-19 的影响、按细分市场分析，它提供了竞争条件和概况等系统信息大公司。

目录

第 1 章执行摘要

第 2 章全球高脂血症市场：定义和范围

第三章世界高脂血症：市场动态

  • 高脂血症市场：影响分析（2020-2028）

第 4 章全球高脂血症市场：行业分析

  • 波特五力模型
  • PEST 分析
  • 投资采用模式
  • 分析师建议和结论
  • 主要投资机会
  • 关键成功策略

第 5 章风险评估：COVID-19 的影响

    • 评估 COVID-19 对行业的整体影响
    • COVID-19 前后的市场情景

第 6 章全球高脂血症市场：按类型

  • 市场快照
  • 成就：潜力分析
  • 市场规模估计和预测（2018-2028）
  • 细分分析
    • 家庭
    • 获得

第 7 章全球高脂血症市场：按治疗方法

  • 市场快照
  • 成就：潜力分析
  • 市场规模估计和预测（2018-2028）
  • 细分分析
    • 他汀类药物
    • 胆汁酸阻滞
    • 胆固醇吸收抑製剂
    • 贝特酸衍生物
    • 组合
    • 其他

第 8 章全球高脂血症市场：按分销渠道

  • 市场快照
  • 成就：潜力分析
  • 市场规模估计和预测（2018-2028）
  • 细分分析
    • 医院药房
    • 零售药店
    • 网上药店
    • 其他

第9章全球高脂血症市场：区域分析

  • 区域市场概况
  • 北美
    • 美国
    • 加拿大
  • 欧洲快照
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 意大利
    • 其他欧洲
  • 亚太地区快照
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 韩国
    • 其他亚太地区
  • 拉丁美洲快照
    • 巴西
    • 墨西哥
  • 其他领域

第10章竞争态势

  • 主要市场策略
  • 公司简介
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Novartis AG
    • Johnson & Johnson Private Limited
    • Sun Pharmaceutical Industries Ltd.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Regeneron Pharmaceuticals Inc.

第11章 调查流程

Global Hyperlipidemia Market is valued at approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2028. Hyperlipidemia is also known as high cholesterol or dyslipidemia. It is a condition there are high levels of fat particles (lipids) present in the blood. The rising prevalence of hyperlipidemia, increasing investment in healthcare infrastructure, and growing number of geriatric populations are the primary factors fostering the market demand across the globe. For instance, as per the World Health Organization (WHO), the global population aged 60 years and above is expected to rise from 605 million in 2000 to 2 billion by the year 2050. Consequentially, the increasing aged population is more prone to get affected by a variety of diseases, which is surging the market demand across the globe. However, the high cost associated with the treatment and shortage of skilled professionals impede the growth of the market over the forecast period of 2022-2028. Also, an increase in the number of research and development activities and rising drug approvals and launches are anticipated to act as catalyzing factors for the market demand during the forecast period.

The key regions considered for the global Hyperlipidemia Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the increasing incidences of hyperlipidemia, along with rising technological developments. Whereas, Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as the growing expenditure on healthcare facilities, as well as the increasing geriatric population, would create lucrative growth prospects for the Hyperlipidemia Market across the Asia-Pacific region.

Major market players included in this report are:

Teva Pharmaceutical Industries Ltd.

Pfizer Inc.

GlaxoSmithKline plc

Novartis AG

Johnson & Johnson Private Limited

Sun Pharmaceutical Industries Ltd.

Merck & Co., Inc.

Bristol-Myers Squibb Company

Eli Lilly and Company

Regeneron Pharmaceuticals Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

Familial

Acquired

By Treatment:

Statins

Bile Acid Sequestrants

Cholesterol Absorption Inhibitors

Fibric Acid Derivatives

Combination

Others

By Distribution Channel:

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019, 2020

Base year - 2021

Forecast period - 2022 to 2028

Target Audience of the Global Hyperlipidemia Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million)
    • 1.2.1. Hyperlipidemia Market, by Region, 2020-2028 (USD Million)
    • 1.2.2. Hyperlipidemia Market, by Type, 2020-2028 (USD Million)
    • 1.2.3. Hyperlipidemia Market, by Treatment, 2020-2028 (USD Million)
    • 1.2.4. Hyperlipidemia Market, by Distribution Channel, 2020-2028 (USD Million)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Hyperlipidemia Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Hyperlipidemia Market Dynamics

  • 3.1. Hyperlipidemia Market Impact Analysis (2020-2028)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising prevalence of hyperlipidemia
      • 3.1.1.2. Growing number of geriatric population
    • 3.1.2. Market Challenges
      • 3.1.2.1. High cost associated with the treatment
      • 3.1.2.2. Dearth of skilled professionals
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increase in the number of research and development activities
      • 3.1.3.2. Rising drug approvals and launches

Chapter 4. Global Hyperlipidemia Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2028)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion
  • 4.5. Top investment opportunity
  • 4.6. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

    • 5.1.1. Assessment of the overall impact of COVID-19 on the industry
    • 5.1.2. Pre COVID-19 and post COVID-19 market scenario

Chapter 6. Global Hyperlipidemia Market, by Type

  • 6.1. Market Snapshot
  • 6.2. Global Hyperlipidemia Market by Type, Performance - Potential Analysis
  • 6.3. Global Hyperlipidemia Market Estimates & Forecasts by Type, 2018-2028 (USD Million)
  • 6.4. Hyperlipidemia Market, Sub Segment Analysis
    • 6.4.1. Familial
    • 6.4.2. Acquired

Chapter 7. Global Hyperlipidemia Market, by Treatment

  • 7.1. Market Snapshot
  • 7.2. Global Hyperlipidemia Market by Treatment, Performance - Potential Analysis
  • 7.3. Global Hyperlipidemia Market Estimates & Forecasts by Treatment, 2018-2028 (USD Million)
  • 7.4. Hyperlipidemia Market, Sub Segment Analysis
    • 7.4.1. Statins
    • 7.4.2. Bile Acid Sequestrants
    • 7.4.3. Cholesterol Absorption Inhibitors
    • 7.4.4. Fibric Acid Derivatives
    • 7.4.5. Combination
    • 7.4.6. Others

Chapter 8. Global Hyperlipidemia Market, by Distribution Channel

  • 8.1. Market Snapshot
  • 8.2. Global Hyperlipidemia Market by Distribution Channel, Performance - Potential Analysis
  • 8.3. Global Hyperlipidemia Market Estimates & Forecasts by Distribution Channel, 2018-2028 (USD Million)
  • 8.4. Hyperlipidemia Market, Sub Segment Analysis
    • 8.4.1. Hospital Pharmacy
    • 8.4.2. Retail Pharmacy
    • 8.4.3. Online Pharmacy
    • 8.4.4. Others

Chapter 9. Global Hyperlipidemia Market, Regional Analysis

  • 9.1. Hyperlipidemia Market, Regional Market Snapshot
  • 9.2. North America Hyperlipidemia Market
    • 9.2.1. U.S. Hyperlipidemia Market
      • 9.2.1.1. Type breakdown estimates & forecasts, 2018-2028
      • 9.2.1.2. Treatment breakdown estimates & forecasts, 2018-2028
      • 9.2.1.3. Distribution Channel breakdown estimates & forecasts, 2018-2028
    • 9.2.2. Canada Hyperlipidemia Market
  • 9.3. Europe Hyperlipidemia Market Snapshot
    • 9.3.1. U.K. Hyperlipidemia Market
    • 9.3.2. Germany Hyperlipidemia Market
    • 9.3.3. France Hyperlipidemia Market
    • 9.3.4. Spain Hyperlipidemia Market
    • 9.3.5. Italy Hyperlipidemia Market
    • 9.3.6. Rest of Europe Hyperlipidemia Market
  • 9.4. Asia-Pacific Hyperlipidemia Market Snapshot
    • 9.4.1. China Hyperlipidemia Market
    • 9.4.2. India Hyperlipidemia Market
    • 9.4.3. Japan Hyperlipidemia Market
    • 9.4.4. Australia Hyperlipidemia Market
    • 9.4.5. South Korea Hyperlipidemia Market
    • 9.4.6. Rest of Asia Pacific Hyperlipidemia Market
  • 9.5. Latin America Hyperlipidemia Market Snapshot
    • 9.5.1. Brazil Hyperlipidemia Market
    • 9.5.2. Mexico Hyperlipidemia Market
  • 9.6. Rest of The World Hyperlipidemia Market

Chapter 10. Competitive Intelligence

  • 10.1. Top Market Strategies
  • 10.2. Company Profiles
    • 10.2.1. Teva Pharmaceutical Industries Ltd.
      • 10.2.1.1. Key Information
      • 10.2.1.2. Overview
      • 10.2.1.3. Financial (Subject to Data Availability)
      • 10.2.1.4. Product Summary
      • 10.2.1.5. Recent Developments
    • 10.2.2. Pfizer Inc.
    • 10.2.3. GlaxoSmithKline plc
    • 10.2.4. Novartis AG
    • 10.2.5. Johnson & Johnson Private Limited
    • 10.2.6. Sun Pharmaceutical Industries Ltd.
    • 10.2.7. Merck & Co., Inc.
    • 10.2.8. Bristol-Myers Squibb Company
    • 10.2.9. Eli Lilly and Company
    • 10.2.10. Regeneron Pharmaceuticals Inc.

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Hyperlipidemia Market, report scope
  • TABLE 2. Global Hyperlipidemia Market estimates & forecasts by Region 2018-2028 (USD Million)
  • TABLE 3. Global Hyperlipidemia Market estimates & forecasts by Type 2018-2028 (USD Million)
  • TABLE 4. Global Hyperlipidemia Market estimates & forecasts by Treatment 2018-2028 (USD Million)
  • TABLE 5. Global Hyperlipidemia Market estimates & forecasts by Distribution Channel 2018-2028 (USD Million)
  • TABLE 6. Global Hyperlipidemia Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 7. Global Hyperlipidemia Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 8. Global Hyperlipidemia Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 9. Global Hyperlipidemia Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 10. Global Hyperlipidemia Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 11. Global Hyperlipidemia Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 12. Global Hyperlipidemia Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 13. Global Hyperlipidemia Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 14. Global Hyperlipidemia Market by segment, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 15. Global Hyperlipidemia Market by region, estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 16. U.S. Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 17. U.S. Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 18. U.S. Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 19. Canada Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 20. Canada Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 21. Canada Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 22. UK Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 23. UK Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 24. UK Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 25. Germany Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 26. Germany Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 27. Germany Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 28. RoE Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 29. RoE Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 30. RoE Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 31. China Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 32. China Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 33. China Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 34. India Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 35. India Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 36. India Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 37. Japan Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 38. Japan Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 39. Japan Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 40. RoAPAC Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 41. RoAPAC Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 42. RoAPAC Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 43. Brazil Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 44. Brazil Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 45. Brazil Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 46. Mexico Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 47. Mexico Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 48. Mexico Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 49. RoLA Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 50. RoLA Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 51. RoLA Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 52. Row Hyperlipidemia Market estimates & forecasts, 2018-2028 (USD Million)
  • TABLE 53. Row Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 54. Row Hyperlipidemia Market estimates & forecasts by segment 2018-2028 (USD Million)
  • TABLE 55. List of secondary sources, used in the study of global Hyperlipidemia Market
  • TABLE 56. List of primary sources, used in the study of global Hyperlipidemia Market
  • TABLE 57. Years considered for the study
  • TABLE 58. Exchange rates considered

LIST OF FIGURES

List of figures

  • FIG 1. Global Hyperlipidemia Market, research methodology
  • FIG 2. Global Hyperlipidemia Market, market estimation techniques
  • FIG 3. Global market size estimates & forecast methods
  • FIG 4. Global Hyperlipidemia Market, key trends 2021
  • FIG 5. Global Hyperlipidemia Market, growth prospects 2022-2028
  • FIG 6. Global Hyperlipidemia Market, porters 5 force model
  • FIG 7. Global Hyperlipidemia Market, pest analysis
  • FIG 8. Global Hyperlipidemia Market, value chain analysis
  • FIG 9. Global Hyperlipidemia Market by segment, 2018 & 2028 (USD Million)
  • FIG 10. Global Hyperlipidemia Market by segment, 2018 & 2028 (USD Million)
  • FIG 11. Global Hyperlipidemia Market by segment, 2018 & 2028 (USD Million)
  • FIG 12. Global Hyperlipidemia Market by segment, 2018 & 2028 (USD Million)
  • FIG 13. Global Hyperlipidemia Market by segment, 2018 & 2028 (USD Million)
  • FIG 14. Global Hyperlipidemia Market, regional snapshot 2018 & 2028
  • FIG 15. North America Hyperlipidemia Market 2018 & 2028 (USD Million)
  • FIG 16. Europe Hyperlipidemia Market 2018 & 2028 (USD Million)
  • FIG 17. Asia Pacific Hyperlipidemia market 2018 & 2028 (USD Million)
  • FIG 18. Latin America Hyperlipidemia Market 2018 & 2028 (USD Million)
  • FIG 19. Global Hyperlipidemia Market, company market share analysis (2021)